187 related articles for article (PubMed ID: 38570449)
1. The Abundance of KRAS and RAS Gene Mutations in Cancer.
Stites EC
Methods Mol Biol; 2024; 2797():13-22. PubMed ID: 38570449
[TBL] [Abstract][Full Text] [Related]
2. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
[TBL] [Abstract][Full Text] [Related]
4. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
5. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
[TBL] [Abstract][Full Text] [Related]
7. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
Tsuchida N; Murugan AK; Grieco M
Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
[TBL] [Abstract][Full Text] [Related]
8. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
9. Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.
Sasaki H; Okuda K; Kawano O; Endo K; Yukiue H; Yokoyama T; Yano M; Fujii Y
Oncol Rep; 2007 Sep; 18(3):623-8. PubMed ID: 17671710
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.
Morris VK; Lucas FAS; Overman MJ; Eng C; Morelli MP; Jiang ZQ; Luthra R; Meric-Bernstam F; Maru D; Scheet P; Kopetz S; Vilar E
Ann Oncol; 2014 Oct; 25(10):2008-2014. PubMed ID: 25009008
[TBL] [Abstract][Full Text] [Related]
12. Extended-spectrum of
Basdemirci M; Zamani A; Zamani AG; Findik S; Yildirim MS
Indian J Cancer; 2022; 59(2):236-243. PubMed ID: 34380837
[TBL] [Abstract][Full Text] [Related]
13. Molecular epidemiology and diagnostics of KRAS mutations in human cancer.
Timar J; Kashofer K
Cancer Metastasis Rev; 2020 Dec; 39(4):1029-1038. PubMed ID: 32725342
[TBL] [Abstract][Full Text] [Related]
14. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.
Johnson C; Burkhart DL; Haigis KM
Cancer Discov; 2022 Apr; 12(4):913-923. PubMed ID: 35373279
[TBL] [Abstract][Full Text] [Related]
15. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
[TBL] [Abstract][Full Text] [Related]
16. Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion.
Quinlan MP; Settleman J
Cell Cycle; 2008 May; 7(10):1332-5. PubMed ID: 18418066
[TBL] [Abstract][Full Text] [Related]
17. Origin and Evolution of RAS Membrane Targeting.
García-España A; Philips MR
Oncogene; 2023 May; 42(21):1741-1750. PubMed ID: 37031342
[TBL] [Abstract][Full Text] [Related]
18. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients.
Benmokhtar S; Laraqui A; El Boukhrissi F; Hilali F; Bajjou T; Jafari M; El Zaitouni S; Baba W; El Mchichi B; Elannaz H; Lahlou IA; Chahdi H; Oukabli M; Mahfoud T; Tanz R; Ichou M; Ennibi K; Dakka N; Sekhsokh Y
Asian Pac J Cancer Prev; 2022 Nov; 23(11):3725-3733. PubMed ID: 36444585
[TBL] [Abstract][Full Text] [Related]
20. The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
Costigan DC; Dong F
Genes Chromosomes Cancer; 2020 Mar; 59(3):152-159. PubMed ID: 31589789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]